Aptamers are single-stranded nucleic acids (usually DNA or RNA) that can bind to specific target molecules with high affinity and specificity. They are created through an iterative process called SELEX (Systematic Evolution of Ligands by EXponential enrichment) which involves the in vitro selection of a library of random sequences. Through SELEX, aptamers can be used to recognize and bind to virtually any molecular target of interest, including proteins, small molecules, and even larger molecules such as viruses. Aptamers are often used in a variety of applications, including drug discovery, diagnostics, therapeutics, and research.
Currently, aptamers market is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period. Growth of aptamers market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages of aptamers as compared to antibodies, rising investment in pharmaceutical RD, and rising prevalence of chronic and rare diseases to increase the demand for aptamer-based therapeutics and diagnostics. Growth in the venture capital funding for research on aptamers and growing collaborations with research institutes and pharmaceutical companies are also expected to offer a wide range of growth opportunities to players in the market. On the other hand, low market acceptance as compared to antibodies is likely to restrain the market growth while shortage of skilled trained professionals may challenge market growth to a certain extent.
Request for assumptions how numbers were triangulated.
https://www.marketsandmarkets.com/requestsampleNew.asp?id=1167
Market Growth Drivers
- Rising number of clinical trials to develop aptamer-based therapeutics
- Rising awareness of the advantages of aptamers over antibodies
- Investments in pharmaceutical RD
- Rising prevalence of chronic and rare diseases
Market Growth Opportunities
- Growth in the venture capital funding for research on aptamers
- Growing collaborations with research institutes and pharmaceutical
Market Challenges
- Shortage of skilled trained professionals
- processes are highly technical
The prominent players operating in the aptamers market are Aptamer Group (UK), Raptamer Discovery Group (US), SomaLogic Inc., (US), Aptamer Sciences, Inc. (South Korea), Aptagen, LLC (US), Maravai Lifesciences (US), Kaneka Corporation (Japan), NeoVentures Biotechnology Inc. (Canada), Aptus Biotech (Spain), Base Pair Biotechnologies (US), AMSBIO (UK), Novaptech (France), Bio-Techne (US)
Aptamer Group (UK) has developed a cutting edge Optimer technology, which is used to offer aptamer-based solutions in the market. This unique technology has enabled the company to strengthen its position in the market. The company focuses on expanding its reach into diagnostic and therapeutic applications. The company is developing Optimer therapeutics for treating myeloid cancer, renal disease, and hematological cancer. In the last three years, the company has focused on collaborations and agreements to expand its geographic reach and the capabilities of Optimer technology in therapeutics. It recently collaborated with various diagnostic and pharmaceutical companies to determine the potential for aptamers as therapeutic agents and in diagnostics. This has enabled the company to increase its foothold in the market.
Raptamer Discovery Group (US) has focused on developing next-generation aptamers for diagnostic and therapeutic applications. The company employs Raptamer technology for developing these aptamers. The company has a strong customer base including pharmaceutical companies and academic research institutes across the globe. The company has received funding for developing aptamer-based therapeutic from various government institutes such as National Aeronautics and Space Agency (NASA) and the National Institutes of Health (NIH). This has provided the company a gateway to expand its horizon into therapeutics development applications.
SomaLogic Inc. (US) is one of the leading players in aptamer market. The company has strived to offer products and services for therapeutics development, diagnostics, and research. This has enabled the company to secure a strong foothold in the market. Its contribution to the aptamers market through mergers, collaborations, and product launches has made SomaLogic a prominent player in this market. Additionally, the company has received funding from various investors for commercializing technology platform. These strategies have enabled the company to maintain its leadership position in the market.
Download an Illustrative Overview:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1167
Objectives of the Study
- To define, describe, and forecast the aptamers market based on type, technology, application, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa
- To profile key market players and comprehensively analyze their product portfolios, market shares, and core competencies
- To track and analyze competitive developments, such as product launches, expansions, acquisitions, agreements, and collaborations in the aptamers market
Recent Developments
- In August 2021, Aptamer Group, Ltd. and BizCom Japan, Inc. entered into a distribution and marketing agreement to market Optimer discovery and development services in Japan.
- In August 2021, Aptamer Group entered a partnership with ProAxsis Limited. As per the partnership, Aptamer Group will develop validated Optimer ligands against critical targets for ProAxsiss diagnostic assays
- In July 2021, Aptamer Sciences, Inc. was selected by the Korean government to support a non-clinical project for a new drug development project for COVID-19 treatment and vaccine and will receive a research grant of about USD 0.51 million for one year through this project.
Content Source:
https://www.marketsandmarkets.com/Market-Reports/aptamers-technology-market-1167.html
https://www.marketsandmarkets.com/PressReleases/aptamers-technology.asp
